BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of hepatocellular carcinoma (HCC) will change dramatically through 2023 as new therapies gain approval and launch for second-line treatment of advanced HCC following disease progression/intolerance to first-line Nexavar (Bayer HealthCare/Amgen/Onyx) treatment. The launch of novel therapies—tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) and Cyramza (Eli Lilly)—for use in the second-line setting will provide treatment options in a patient population for which there is currently no standard of care.
Other key findings from the Niche Markets and Rare Diseases report entitled Hepatocellular Carcinoma:
- Diagnosed incident cases: The number of diagnosed incident cases of HCC in the major markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan) will increase by more than 1 percent annually over 2013 to 2023, driven by the aging population and an increase in risk attributable to changes in exposure to risk-factors associated with HCC.
- Personalized drug treatment: The expected approval of tivantinib, a multitargeted tyrosine kinase inhibitor that targets c-MET, will mark a shift towards personalized drug-treatment of HCC.
- Treatment options for advanced HCC: The expected approval of Cyramza will diversify treatment options for patients with advanced HCC and will result in more patients receiving treatment in the second-line setting.
- Generic erosion of Nexavar: Nexavar, the key branded therapy used in treatment of advanced HCC, will undergo generic erosion during the 2013 to 2023 forecast period, tempering the growth of the HCC market.
- Lack of emerging novel agents: The anticipated lack of launches of novel drug therapies for early- and intermediate-stage HCC will hinder the HCC drug therapy market from expanding beyond the advanced disease setting.
Comments from Decision Resources Group Senior Analyst Karen Pomeranz, M.Sc., Ph.D.:
- "The majority of agents in the HCC pipeline are being examined in the second-line advanced setting. During the course of the next ten years we expect the launch of two new therapies in this setting—Cyramza and tivantinib—which will help address the large unmet need for therapies following disease progression on Nexavar."
- "Although we anticipate that the unmet need for new treatment options in the second-line advanced HCC setting will be addressed to some extent by Cyramza and tivantinib, a significant unmet need for novel therapies for the earlier stages of the disease will likely remain."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group